Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study

Supportive Care in Cancer

Volumn 25, Issue 9, 2017, Pages 2779-2786

  Mafodda, Antonino ^a   Giuffrida, D ^b   Prestifilippo, A ^b   Azzarello, D ^a   Giannicola, R ^a   Mare, M ^b   Maisano, R ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b Istituto Oncologico del Mediterraneo   (Italy)

Author keywords

Chemotherapy related anemia; Hb response; IV iron; Oral iron; Sucrosomial iron

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM; SUCROSOMIAL IRON; UNCLASSIFIED DRUG; IRON;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; ANEMIA; CHEMICALLY INDUCED; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; ORAL DRUG ADMINISTRATION; PSYCHOLOGY;

ADMINISTRATION, ORAL; ANEMIA; DARBEPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; NEOPLASMS; PILOT PROJECTS; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 85017140317     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-017-3690-z     Document Type: Article

References (40)

1. Dicato M, Plawny L, Diederich M (2010) Anemia in cancer. Ann Oncol 21(Suppl 7):vii167–vii172
2. Gascon P (2015) Management of iron-deficiency anemia and functional iron deficiency in cancer patients. Expert Rev Hematology, Rome, 8(S1):1–32
3. Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Annals of Oncology 24(7):1886–1892
4. Pedrazzoli P, Rosti G, Secondino S, Siena S (2009) Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer 115(6):1169–1173
5. Steinmetz HT (2012) The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 3(3):177–191
6. Bohlius J, Tonia T, Nuesch E, Juni P, Fey MF, Egger M et al (2014) Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 111(1):33–45
7. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ et al (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22(8):2197–2206
8. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15):2293–2306
9. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270
10. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Somerfield MR, Temin S (2010) American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract 6(6):317–320
11. Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C et al (2012) Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw: JNCCN 10(5):628–653
12. Schrijvers D, De Samblanx H, Roila F (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244–v247
13. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22(7):1301–1307
14. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12(2):231–242
15. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26(10):1619–1625
16. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.V. Iron. Ann Oncol 23(8):1954–1962
17. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S (2012) Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 138(2):179–187
18. Karlsson T (2011) Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents. ISRN Hematol 2011:108397
19. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U et al (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol (Stockholm, Sweden) 52(1):18–29
20. AIFA (2013) Nota Informativa importante su medicinali contententi ferro per via endovenosa. Available at: http://www.aifa.gov.it/content/nota-informativa-importante-su-medicinali-contenenti-ferro-25102013. Accessed 7 April 2017.
21. European Medicine Authority (2013) New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines EMA/579491/2013: EMA [updated 13 September 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf
22. Brilli E, Romano A, Fabiano A, Zambito Y, Di Raimondo F, Tarantino G (2016) Sucrosomial® technology is able to promote ferric iron absorption: pre-clinical and clinical evidences. Blood J 128(22):3618
23. Tarantino G, Brilli E, Zambito Y, Giordano G, Equitani F (2015) Sucrosomial Iron®: a new highly Bioavaible oral iron supplement. Blood 126(23):4561
24. Barni S (2015) 3rd Mediterranean Multidisciplinary Course on Iron Anemia April, 17(th)-18(th) 2015, Rome, Italy. Expert Rev Hematol 8(Suppl 1):S1–s32
25. Barni S (2016) 4th Mediterranean Multidisciplinary Course on Iron Anemia April 29th–30th 2016, Madrid, Spain. Expert Rev Hematol 9(sup1):1–42
26. Parisi F, Berti C, Mandò C, Martinelli A, Mazzali C, Cetin I (2016) Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. The Journal of Maternal-Fetal & Neonatal Medicine 1–21
27. Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B (2015) Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant 30(4):645–652
28. European Medicine Authority (2013) Aranesp product information sheet. [Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000332/WC500026141.pdf.
29. Gunnars B, Nygren P, Glimelius B (2001) Assessment of quality of life during chemotherapy. Acta Oncol (Stockholm, Sweden) 40(2–3):175–184
30. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 13(2):63–74
31. Nemeth E, Ganz T (2006) Hepcidin and iron-loading anemias. Haematologica 91(6):727–732
32. Nemeth E, Ganz T (2014) Anemia of inflammation. Hematol Oncol Clin N Am 28(4):671–681 vi
33. Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12(2):107–111
34. Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117(17):4425–4433
35. Tarantino G, Brilli E, Giordano G, Torelli A, Equitani F (2015) Innovative oral iron supplement (Sucrosomial Iron®) is able to downregulate Hepcidin release during inflammation: in vitro study. Blood 125(23):4563
36. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674):1532–1542
37. Kara O, Dizdar O, Altundag K (2008) Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. JAMA 300(24):2855 author reply -7
38. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25(9):1027–1032
39. Giordano G, Mondello P, Tambaro R, Perrotta N, D'Amico F, D'Aveta A et al (2015) Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: a retrospective real-life approach. Mol Clin Oncol 3(4):781–784
40. Steinmetz T, Schroder J, Plath M, Link H, Vogt M, Frank M et al (2016) Antianemic treatment of cancer patients in German routine practice: data from a prospective cohort study-the tumor anemia registry. Anemia 2016:8057650